PeptideTreatments
Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)

CJC-1295: Research & Evidence

Emerging Evidence

Published research, clinical trial data, and evidence grading for CJC-1295 across studied indications.

Back to CJC-1295 overview

Research Summary

CJC-1295 was developed by ConjuChem Biotechnologies and reached Phase II clinical trials. The pivotal Teichman et al. (2006) dose-escalation study in 21 healthy adults demonstrated dose-dependent GH increases of 2- to 10-fold persisting 6+ days, with IGF-1 elevation of 1.5- to 3-fold for 9-11 days after single subcutaneous doses of 30-120 mcg/kg. A companion study (Alba et al., 2006) confirmed that GH pulsatility was preserved during continuous CJC-1295 stimulation — trough GH, mean GH, and pulsatile GH secretion all increased without loss of episodic release. Jette et al. (2005) established the DAC-albumin bioconjugation mechanism in rats, identifying CJC-1295 as a long-lasting GRF analog. A Phase II trial (NCT00267527) evaluating CJC-1295 in 120 HIV patients with visceral obesity was terminated. The program was discontinued following a subject death during clinical trials. CJC-1295 remains not FDA-approved.

Evidence by Indication (3 indications)

Indication Tier Trials Summary
GH deficiency Tier B 5 Phase II data as GHRH analog
Body composition Tier C 3 Limited controlled data for body recomposition
Sleep quality Tier D 1 Anecdotal and single small trial

Graded using our evidence tier methodology.

Citations (9 sources)

  1. 1. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Clinical Trial

    Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Bhatt R (2006), The Journal of Clinical Endocrinology and Metabolism

  2. 2. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog Clinical Trial

    Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Storch MK, Bhatt R, Sverdloff R, Hartman ML, Veldhuis JD, Salvatori R (2006), The Journal of Clinical Endocrinology and Metabolism

  3. 3. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Study

    Jette L, Leger R, Thibaudeau K, Benquet C, Robitaille M, Castaigne JP, Bhatt R (2005), Endocrinology

  4. 4. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse Study

    Ionescu M, Bhatt R, Gagnon C, et al. (2006), American Journal of Physiology. Endocrinology and Metabolism

  5. 5. From GHRH to IGF-1 and downstream: clinical phenotypes and biological mechanisms Review

    Veldhuis JD, Bowers CY (2012), Endocrinology Review

  6. 6. Central and peripheral regulation of the GH/IGF-1 axis: GHRH and beyond Review

    Multiple authors (2024), Reviews in Endocrine and Metabolic Disorders

  7. 7. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions Study

    Grace F, Baker JS (2016), Substance Use and Misuse

  8. 8. The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects Review

    Multiple authors (2018), Frontiers in Endocrinology

  9. 9. Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry Study

    Multiple authors (2026), Journal of Pharmaceutical and Biomedical Analysis